ASTN2

Across TCGA pan-cancer cohorts, ASTN2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ASTN2 data layer compared with 24 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ASTN2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ASTN2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and CCRCC show a favorable association.

LUAD, LSCC, and CCRCC are the cancer types where ASTN2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	III,IV	0.292	0.871	.001	24	view →
LSCC	DFS	Quartile	All	0.855	0.533	.022	7	view →
CCRCC	DFS	Tertile	All	1.000	0.641	.028	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ASTN2–LUAD (DFS)

Open the LUAD breakdown →